BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 30191366)

  • 1. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequencies of
    Scherf-Clavel M; Weber H; Unterecker S; Müller DJ; Deckert J
    World J Biol Psychiatry; 2024 Apr; 25(4):214-221. PubMed ID: 38493365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
    Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
    J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting.
    Mostafa S; Polasek TM; Sheffield LJ; Huppert D; Kirkpatrick CMJ
    Front Psychiatry; 2021; 12():724170. PubMed ID: 34489765
    [No Abstract]   [Full Text] [Related]  

  • 7. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
    Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
    Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity.
    D'Attis S; Massari S; Mazzei F; Maio D; Vergallo I; Mauro S; Minelli M; Bozzetti MP
    Int Arch Allergy Immunol; 2019; 179(3):173-186. PubMed ID: 30943525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic profile of a central European urban random population-Czech population.
    Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
    PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
    Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
    JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
    Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
    Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
    Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
    Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
    Naujokaitis D; Asmoniene V; Kadusevicius E
    Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese.
    He L; Chen S; Li J; Xie X; Huang L; Kuang Y; Xu K; Huang W; Zhao Y; Yang G; Guo C
    Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1659-1663. PubMed ID: 32469422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.